American College of Toxicology 2026 Annual Meeting
ACT 2026 Annual Meeting
November 15, 2026 – November 18, 2026
San Antonio, TX, USA
The International Council for Harmonization (ICH) S7A guideline on safety pharmacology studies is aimed at protecting clinical trial participants and patients. The guidelines were first published in 2000 and have not been updated in more than 25 years. In that time, science and technology has advanced as have the diversity of therapeutic modalities. Given this, there has been an increasing interest in revising the S7A guidelines. A revision requires global consensus on the need and priorities as well as harmonization across regions and sectors.
Links to relevant ICH documents are available here:
Original S7A Guidelines
Standard Operating Procedure of the ICH Working Groups
Five key pillars have been identified as opportunities for further clarification and revision in an updated S7A. The weight of evidence (WoE) approach is foundational and the utility of safety pharmacology is based on decision-shaping evidence. The ‘context of use’ is the focused topic of the generated evidence. Ability to embrace broad spectrum of human relevant approaches from in silico, in vitro to in vivo. NAMs for safety pharmacology include: Broad secondary pharmacology assessments, Complex Humanized in vitro cell models, Augmented in vivo assessments, especially inclusion in toxicology studies. Methods can be qualified (WoE determined) against the context of use. The ultimate scheme becomes modality- and technology-agnostic.

In an effort to facilitate conversations ahead of a potential revision, HESI Global has convened a Steering Team consisting of global representatives from regulatory agencies and pharmaceutical industry. HESI Global provides a neutral forum to bring together theses groups and allow for opportunities to track ongoing activities, communications and discussion of key opportunities and gaps in the potential revision of S7A.
HESI Global is also communicating with additional stakeholder groups that represent key partners in the ecosystem to ensure consistent messaging and collection of critical feedback on a potential revision
US Food and Drug Administration
US Food and Drug Administration
Pharmaceuticals and Medical Devices Agency
European Medicines Agency
UCB
Amgen
Eisai
Dr. Claire O’Brien holds a PhD in Pharmacology and Toxicology from the University of California, Davis, and an MPH in Environmental Health from San Diego State University. She comes to HESI with experience a Regulatory Specialist at a biotech company where she helped to develop a regulatory strategy for bringing innovative infant nutrition products to market. She also has experience in safety assessment and toxicology of dietary supplements, educational outreach on environmental health topics within a community setting, and as a lead clinical trials coordinator for a major research study. Dr. O’Brien will work on the Cardiac Safety Committee, PBPK Committee, and the PATB program.
Associate Director
Director, Center for Translational Sciences (CTS)
jpierson@hesiglobal.orgJennifer Pierson received her BS in Biology in 2005 from Villanova University and her Master of Public Health in 2007 from Drexel University. She has been with HESI Global since 2012 and is currently the Associate Director. In addition to committee management, Jennifer provides strategic leadership in identifying emerging science topics as well as providing management and insights into grant activities for the organization. Her prior experience includes working in research laboratories and at a local health department, where she focused on epidemiological investigations. She also has extensive experience in project management and has published numerous papers, reports, guidelines, and white papers on public health issues.
Alexandra Taraboletti joined HESI in 2024 as a Scientific Program Manager. She received her BS in Chemistry from the University of Central Florida and her PhD in Chemistry from the University of Akron. She completed her postdoctoral studies in Tumor Biology at Georgetown University. Prior to joining HESI, she served as an Assistant Professor at the University of the District of Columbia (UDC), focusing on omics-driven environmental biology. She also contributed to the National Heart Lung and Blood Institute (NHLBI) Workshop Support Program (WSP) as a scientific writer, authoring numerous publications, white papers, and executive summaries on human and environmental health topics. At HESI, she currently supports the Genetic Toxicology Technical Committee (GTTC) and the Cardiac Safety Committee.
November 15, 2026 – November 18, 2026
San Antonio, TX, USA
American College of Toxicology 2026 Annual Meeting
September 26, 2026 – September 29, 2026
Bethesda, MD, USA
American College of Clinical Pharmacology 2026 Annual Meeting
September 21, 2026 – September 23, 2026
Montreal, Canada
2026 Safety Pharmacology Society Annual Meeting
September 13, 2026 – September 16, 2026
Vienna, Austria
July 28, 2026
Silver Spring, Maryland, USA
Workshop on Advancing NAM Integration into the ICH S7A Guidance
July 1, 2026 – July 3, 2026
Osaka, Japan
53rd Annual Meeting of the Japanese Society of Toxicology
The Journal of Pharmacological & Toxicological Methods (JPTM) is the leading international journal devoted exclusively to experimental procedures used by pharmacologists and toxicologists and publishes focused issues that are devoted to a single research topic. A special issue focused on “Advancing Safety Pharmacology for ICH S7A(R1): From Workshop Insights to Future Frameworks” is anticipated in Fall 2026. This issue will feature manuscripts on topics related to the S7A revision and background information. It will feature articles from stakeholders in the pharmaceutical industry as well as NGOs and international regulators.
Valentin et al., 2026. Revisiting ICH S7A after 25 years: Outcomes of a multi-stakeholder workshop and strategic pillars for modernizing safety pharmacology. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2026.106096
Valentin and Leishman, 2025. Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2025.105795
Valentin et al., 2025. Results from an EFPIA, JPMA, PhRMA industry survey on reopening and revamping the ICH S7A guidance on safety and secondary pharmacology. Journal of Pharmacological and Toxicological Methods. https://doi.org/10.1016/j.vascn.2025.107763
Valentin and Leishman, 2023. 2000–2023 over two decades of ICH S7A: has the time come for a revamp? Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2023.105368.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.